U.S. Government Should Commit More Funding, Scientific Research To TB Diagnosis, Treatment
Forbes: World TB Day — How Budget Cuts Threaten Progress In Tuberculosis Globally
Judy Stone, Forbes contributor and infectious disease specialist
“…For the first time in 40+ years, new drugs are being tested in major Phase III clinical trials against MDR (multidrug-resistant) and XDR (extensively drug-resistant) TB. But without pharma and governments stepping up more, it won’t be enough to help most of those in need, given price and access issues. … With Trump’s proposed budget, slashing [funding] from NIH, and vast sums from foreign aid and other services, these trials will likely be victims of his administration’s mistaken priorities. … [T]o have the U.S. government pull back from their important support in this area now would be incredibly short-sighted and misguided. … We have seen what can be accomplished when a concerted effort is made, with sufficient funding, to tackle a major infectious disease. HIV/AIDS has been transformed from a death sentence to being a chronic, but controllable condition. While this success is the result of many different actors, few would argue that PEPFAR, NIAID, and the U.S. government’s significant support for this cause played a large role. … The U.S. government should recall this and commit the same type of sustained funding and scientific effort to control tuberculosis…” (3/24).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.